

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 01 2001

Application of : Hochrainer, D. et al

Serial No. : 09/800,647

Filed : March 7, 2001

For : A two-part capsule to accept pharmaceutical preparations for powder inhalers

Docket No.: 1/1060-1-C1

) Art Unit: 1619

) Examiner: S. Sharareh

TECH CENTER 1600/2980

7/5/01

Assistant Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☐ 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of either a final action under §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first. This Statement is being accompanied by:

☐ A certification as specified in 37 C.F.R. §1.97(e); or

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Assistant Commissioner is hereby authorized to charge payment of the \$240.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.


☐ 1.97(d). This Statement is being filed after the mailing of either a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first, but before payment of the issue fee. This Statement is being accompanied by a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of this Statement, and the petition fee set forth in 37 C.F.R. §1.17(i).

☐ The Assistant Commissioner is hereby authorized to charge payment of the \$130.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

  
Mary-ellen M. Devlin  
Attorney for Applicant(s)  
Reg. No. 27,928

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 798-4866

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, DC 20231

on May 24, 2001

By:   
Mary-ellen M. Devlin  
Reg. No. 27,928